Helus Pharma 12-Month Price Target Cut to $43.72
The 12-month target was cut to $43.72, which the headline says implies 316% upside.
Related stories
Southside Bancshares Q3 earnings snapshot
Southside Bancshares reported third
M impact | EQUITY | Oct 29, 2026, 10:04 AM UTC
Man Infraconstruction Q2 Profit Rises 8.7% to ₹65.2 Crore
Consolidated revenue increased 57.2% year on year to ₹266 crore for the September quarter, from ₹169 crore.
M impact | EQUITY | Oct 29, 2026, 09:53 AM UTC
Laurus Labs Q2 Profit More Than Doubles; Margin Beats Estimates
Laurus Labs said September-quarter net profit more than doubled year on year and revenue and operating earnings beat CNBC-TV18’s estimates. The company also declared a dividend and
M impact | EQUITY | Oct 29, 2026, 09:53 AM UTC
Zhongmin Baihui Retail Group Reports Annual General Meeting Results
The company reported the results of its annual general meeting. The headline also refers to a proposed renewal of the share buyback mandate; the supplied body is truncated.
M impact | EQUITY | Oct 29, 2026, 09:53 AM UTC
Portland General Electric Q3 Earnings Snapshot
Portland General Electric is the subject of a Q3 earnings snapshot; the supplied text does not include any reported results.
M impact | EQUITY | Oct 29, 2026, 09:52 AM UTC
ServiceNow Shares Fall Nearly 18% in Premarket Trading
ServiceNow shares fell nearly 18% in premarket trading after the company reported mixed third-quarter results, with revenue beating expectations and earnings falling short. JPMorga
M impact | EQUITY | Oct 29, 2026, 09:52 AM UTC